PREXILON PRIVATE LIMITED

In their own words

Prexilon Private Limited is a Kerala-based biotechnology startup incorporated on 11 December 2025, focused on building innovative, scalable, and Make-in-India aligned diagnostic solutions to bridge critical gaps in early, affordable, and accurate disease detection. The company is developing a next-generation Point-of-Care Testing (POCT) and AI-enabled diagnostics platform designed to deliver rapid, clinically reliable results outside centralized laboratory environments. Its core innovation is a modular molecular multiplex nucleic-acid diagnostic system with a reusable reader and disposable cartridge architecture, enabling decentralized molecular testing with high accuracy and cost efficiency. In parallel, Prexilon is advancing AI-based early detection and screening workflows, including solutions for neurodegenerative disorders, to support timely diagnosis and preventive healthcare. A provisional patent has been filed with the Indian Patent Office covering the platform architecture and associated diagnostic workflows. By focusing on accessibility, affordability, and scalability, Prexilon aims to improve healthcare outcomes in rural and underserved regions while addressing global diagnostic needs. Operating at the intersection of biotechnology, artificial intelligence, and medical diagnostics, the company emphasizes strong scientific validation, regulatory readiness, and clinical impact. Over the next three years, Prexilon plans to create more than 100 direct and indirect employment opportunities across research and development, AI/ML, product engineering, manufacturing, quality and regulatory functions, and field operations, contributing to skill development, local innovation, and improved access to early diagnosis.

Written by the company on its public Startup India profile. Not verified by us.